- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00303329
Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia Patients
Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Other Patients With Rare Chronic Anemia and Transfusional Iron Overload
A 1-year randomized Phase II core trial was conducted to investigate the efficacy of deferasirox in regularly transfused patients with β-thalassemia and other rare chronic anemia 2 years of age and older. Patients who successfully completed the main trial may continue in the extension trial to receive chelation therapy with deferasirox for up to 3 years. Extension was prolonged to 4 years.
The objective of this study is to assess the long-term safety and efficacy of deferasirox in these patient groups.
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Brugge, Belgium
- Novartis Investigative Site
-
Bruxelles, Belgium
- Novartis Investigative Site
-
Gent, Belgium
- Novartis Investigative Site
-
La Louvière, Belgium
- Novartis Investigative Site
-
Leuven, Belgium
- Novartis Investigative Site
-
-
-
-
-
Montreal, Canada
- Novartis Investigative Site
-
Toronto, Canada
- Novartis Investigative Site
-
-
-
-
-
Creteil, France
- Novartis Investigative Site
-
Le Kremlin Bicetre, France
- Novartis Investigative Site
-
Lille, France
- Novartis Investigative Site
-
Troyes, France
- Novartis Investigative Site
-
-
-
-
-
Duesseldorf, Germany
- Novartis Investigative Site
-
Hannover, Germany
- Novartis Investigative Site
-
Ulm, Germany
- Novartis Investigative Site
-
-
-
-
-
Bologna, Italy
- Novartis Investigative Site
-
Brindisi, Italy
- Novartis Investigative Site
-
Cagliari, Italy
- Novartis Investigative Site
-
Genova, Italy
- Novartis Investigative Site
-
Milan, Italy
- Novartis Investigative Site
-
Pavia, Italy
- Novartis Investigative Site
-
Rome, Italy
- Novartis Investigative Site
-
Torino, Italy
- Novartis Investigative Site
-
-
-
-
-
London, United Kingdom
- Novartis Investigative Site
-
-
-
-
California
-
Oakland, California, United States, 94609-1809
- Children's Hospital and Research Center at Oakland
-
Stanford, California, United States, 94305
- Stanford hospital
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Childres's Hospital Boston
-
-
New York
-
New York, New York, United States, 10021
- New York Presbyterian Hospital
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104-4399
- Children's Hospital of Philadelphia
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients completed the planned 12-month core study
- Female patients who have reached menarche and who are sexually active must use double-barrier contraception, oral contraceptive plus barrier contraceptive, or must have undergone clinically documented total hysterectomy and/or ovariectomy, or tubal ligation
- Written informed consent obtained from the patient and/or legal guardian on the patient's behalf in accordance with the national legislation
Exclusion Criteria:
- Pregnant or breast feeding patients
Other protocol-defined inclusion/exclusion criteria may apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Deferasirox
Deferasirox daily oral dose between 5-40 mg/kg/day
|
Deferasirox available as 125 mg, 250 mg or 500 mg tablets
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) or Deaths
Time Frame: Core study Baseline to the end of the study (up to 60 months)
|
Safety was assessed using reports of adverse events of all participants in this study.
Serious adverse events are those events that resulted in death, were life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, or was a congenital anomaly/birth defect.
|
Core study Baseline to the end of the study (up to 60 months)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Change in Liver Iron Content (LIC) as Assessed by Liver Biopsy at Baseline to the End of the Study
Time Frame: Core study Baseline to end of extension study (up to 60 months)
|
Liver iron concentration was monitored at the start of the core study, the end of the core study, and then at the end of the extension study.
High-risk participants, like participants with rare anemia, were excluded from any further potential liver biopsy, except if required and justified by the Investigator for the general care of the participant.
|
Core study Baseline to end of extension study (up to 60 months)
|
The Absolute Change in Liver Iron Content (LIC) as Assessed by Superconducting Quantum Interference Device (SQUID) From Baseline to End of Study
Time Frame: Core study Baseline to end of extension study (up to 60 months)
|
Liver iron concentration was monitored at the end of the core study and then at the end of the extension study.
High-risk participants, like participants with rare anemia, were excluded from any further potential liver biopsy, except if required and justified by the Investigator for the general care of the participant.
Pediatric participants or participants with a medical contraindication to liver biopsy were allowed the use of SQUID in the extension study.
|
Core study Baseline to end of extension study (up to 60 months)
|
The Absolute Change in Serum Ferritin (μg/L) Levels From Baseline to the End of the Study
Time Frame: Core study Baseline to end of extension study (up to 60 months)
|
Serum ferritin was monitored monthly and the dose of deferasirox was increased or decreased in steps of 5 to 10 mg/kg/day up to a maximum of 40 mg/kg/day if appropriate, every 3 months.
If serum ferritin fell to 500 ng/mL or lower on two consecutive study visits, an interruption of treatment until serum ferritin was more than 500 ng/mL was considered.
|
Core study Baseline to end of extension study (up to 60 months)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Metabolic Diseases
- Hematologic Diseases
- Genetic Diseases, Inborn
- Iron Metabolism Disorders
- Metabolism, Inborn Errors
- Anemia, Hemolytic, Congenital
- Anemia, Hemolytic
- Hemoglobinopathies
- Metal Metabolism, Inborn Errors
- Iron Overload
- Anemia
- Thalassemia
- beta-Thalassemia
- Hemochromatosis
- Hemosiderosis
- Molecular Mechanisms of Pharmacological Action
- Chelating Agents
- Sequestering Agents
- Iron Chelating Agents
- Deferasirox
Other Study ID Numbers
- CICL670A0108E1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anemia
-
SanofiActive, not recruitingWarm Autoimmune Hemolytic Anemia (wAIHA)United States, Austria, China, Denmark, Germany, Hungary, Italy, Spain, United Kingdom
-
SanofiTerminatedWarm Autoimmune Hemolytic Anemia (wAIHA)United Kingdom, Belgium, Netherlands, France, United States, Germany, Hungary, Italy
-
Hospital Universitario Dr. Jose E. GonzalezCompletedPernicious Anemia | Megaloblastic Anemia NosMexico
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingSevere Aplastic Anemia | Idiopathic Aplastic Anemia | Moderate Aplastic Anemia Requiring Transfusions
-
Abdelwahed, Mai Mahmoud Mohamed, M.D.UnknownAnemia During PregnancyEgypt
-
University of California, DavisInstituto Mexicano del Seguro Social; Thrasher Research Fund; Mexican National... and other collaboratorsCompleted
-
Incyte CorporationActive, not recruitingWarm Autoimmune Hemolytic Anemia (wAIHA)Spain, United States, Austria, Belgium, Canada, France, Germany, Israel, Italy, Japan, Netherlands, Poland, United Kingdom
-
Peking Union Medical College HospitalRecruiting
-
Alexion PharmaceuticalsWithdrawnWarm Autoimmune Hemolytic AnemiaUnited States
Clinical Trials on Deferasirox
-
Novartis PharmaceuticalsCompletedTransfusion-dependent AnemiaEgypt, Hungary, Turkey, United States, Bulgaria, Italy, Belgium, Russian Federation, Philippines, France, Malaysia, India, Oman, Panama, Lebanon, Thailand, Tunisia
-
DisperSol Technologies, LLCCompletedThalassemia MajorThailand, United States
-
Novartis PharmaceuticalsCompletedNon-transfusion-dependent Thalassemia | Transfusion-dependent ThalassemiaEgypt, Turkey, Thailand, Lebanon, Morocco, Saudi Arabia, Vietnam
-
Novartis PharmaceuticalsWithdrawnThalassemia (Transfusion Delendent)
-
Novartis PharmaceuticalsCompletedLow and Int 1-risk Myelodysplastic SyndromeGermany, Canada, Korea, Republic of, Sweden, Spain, China, Argentina, Italy, United Kingdom, Algeria
-
Assistance Publique - Hôpitaux de ParisAssociation pour l'Etude des Fonctions Digestives (AEFD)UnknownPorphyria Cutanea TardaFrance
-
NovartisCompletedBeta-Thalassemia | HemosiderosisEgypt, Lebanon, Oman, Saudi Arabia, Syrian Arab Republic
-
Novartis PharmaceuticalsCompletedNon-transfusion Dependent ThalassemiaThailand, Turkey, Italy, Greece, China, United Kingdom, Lebanon, Tunisia
-
City of Hope Medical CenterTerminatedPrimary Myelofibrosis | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Iron Overload | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell... and other conditionsUnited States
-
Crolll GmbhUniversity of Magdeburg; Estimate, GmbHCompletedNon-alcoholic Steatohepatitis | Increased Iron Storage / Disturbed DistributionGermany